Clinical trials: RSV Infections
RSV Infection, Human Metapneumovirus Infection
Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults
This phase 1/2 study will evaluate the safety, reactogenicity and immunogenicity of SCB-1022 and SCB-1033 compared to SCB-1019T (Parts 1 and 2) or Placebo (Part 3).
- Conditions
- RSV Infection, Human Metapneumovirus Infection, Parainfluenza Infection
- Trial name
- NCT06984094
- Testing
- SCB-1019T, SCB-1022, SCB-1033
- Where
- 3 sites in Australia
- Volunteers
- 612 people, healthy volunteers welcome
- Sponsor
- Clover Biopharmaceuticals AUS Pty
RSV Infection
A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose
This study aims to check how safe and well-tolerated a second dose of RSVpreF is when given during later pregnancies, and to see how long the immunity lasts from a single dose given during a previous pregnancy by examining the…
- Trial name
- NCT06866405
- Testing
- RSVpreF
- Where
- 97 sites in United States, Argentina and 2 more
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Pfizer
Respiratory Syncytial Virus (RSV), Respiratory Infection Virus
THRIVE - Trial of Passive Humoral RSV Immunity for Value and Effectiveness
RSV is a leading cause of severe respiratory illness and hospitalisation for young children, with particularly high rates of RSV respiratory infection observed amongst Aboriginal and Torres Strait Islander children living in…
- Trial name
- THRIVE (NCT07578298)
- Testing
- Nirsevimab (RSV-specific monoclonal antibody)
- Where
- Australia
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Menzies School of Health Research
COVID-19, SARS-CoV-2 Infection, RSV
Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)
The purpose of this study is to comprehensively describe the temporal and geographic utilization of COVID-19 therapies used for mild to moderate disease during different periods of SARS-CoV-2 variant circulation as well as to…
- Conditions
- COVID-19, SARS-CoV-2 Infection, RSV, Influenza
- Trial name
- COPE-VA (NCT06160128)
- Where
- United States
- Volunteers
- 400,000 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
RSV Infection
Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of Age
The purpose of this study is to evaluate the infectivity, safety, and immunogenicity of a single dose of a recombinant, live-attenuated respiratory syncytial virus (RSV) vaccine, LID/ΔM2-2/1030s, in RSV-seronegative infants and…
- Trial name
- NCT04520659
- Testing
- RSV LID/ΔM2-2/1030s
- Where
- 3 sites in United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19, SARS-CoV-2 Virus
SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies (Level42)
The goal of this observational study is to evaluate new non-invasive passive surveillance technologies, Level 42 AI imPulse™ Una and TOR devices for the detection of COVID-19, Flu, and/or RSV in asymptomatic and symptomatic…
- Conditions
- COVID-19, SARS-CoV-2 Virus, COVID-19 Pneumonia, Respiratory Infection
- Trial name
- PassiveDetec (NCT05765396)
- Testing
- imPulse™ Systems (Una and TOR) infrasound-to-ultrasound e-stethoscope
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- The Geneva Foundation
RSV Immunization
Prevention of RSV Infection in Infants by Administering Nirsevimab to Infants, With or Without Maternal RSV Vaccination
RSV (which stands for Respiratory Syncytial Virus) is an infection that causes cold-like symptoms and is most common during winter months.
- Trial name
- PIPELINE-RSV-F (NCT07232706)
- Testing
- Nirsevimab, Abrysvo
- Where
- France
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Annecy Genevois
SARS CoV 2 Infection, Respiratory Syncytial Virus (RSV)
Transplacental Transmission of RSV (TTRSV)
Aim 1: To study transplacental transmission of Respiratory Syncytial Virus (RSV) and how this is moderated by other maternal infections during pregnancy Aim 2: To test maternal blood for presence of RSV-specific immunoglobulins…
- Conditions
- SARS CoV 2 Infection, Respiratory Syncytial Virus (RSV), Bronchiolitis, Asthma
- Trial name
- NCT05443607
- Where
- 2 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Tulane University
RSV Infections, RSV Immunisation
A Clinical Trial on Safety in Pregnant Women and How Well the Infant is Protected Against RSV-associated Lower Respiratory Tract Infection When the Pregnant Woman Receives the Approved RSV Vaccine Compared to a Placebo.
Respiratory syncytial virus (RSV) is a virus that often affects children during childhood. Even though most cases of RSV are mild, it can cause serious disease and even death - especially in very young babies, babies born too…
- Conditions
- RSV Infections, RSV Immunisation, Preterm Labour
- Trial name
- NCT06955728
- Testing
- Vaccine
- Where
- 11 sites in Ghana, Kenya and 2 more
- Volunteers
- 13,000 people, healthy volunteers welcome
- Sponsor
- University of Witwatersrand, South Africa
Respiratory Syncytial Virus (RSV), Influenza A(H5N1)
Study of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of Age
The purpose of this study is to evaluate the safety and immunogenicity of different formulations of vaccines encoding the RSV monovalent antigen or the Flu hemagglutinin subtype 5 (H5) antigen in healthy participants aged 18 to…
- Trial name
- NCT07516418
- Testing
- H5 Flu Investigational Medical Product (IMP) 1, H5 Flu IMP 2, H5 Flu IMP 3
- Where
- 6 sites in Australia
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Sanofi
RSV Infection
Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and Children
The purpose of this study is to evaluate the infectivity, safety, and immunogenicity of a single dose of recombinant, live-attenuated respiratory syncytial virus (RSV) vaccines (RSV 6120/∆NS1 or RSV 6120/F1/G2/∆NS1) in…
- Trial name
- NCT03596801
- Testing
- RSV 6120/∆NS1, RSV 6120/F1/G2/∆NS1
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
RSV Infections, Lower Respiratory Tract Infections
Real-World Effectiveness of Nirsevimab Against RSV-Related and All-Cause Respiratory Tract Infections in Chinese Infants
A multicenter, retrospective cohort study based on clinical data from seven tertiary hospitals in China will be undertaken. The study aims to evaluate the real-world effectiveness of Nirsevimab in preventing Respiratory Syncytial…
- Trial name
- NCT07382219
- Testing
- Nirsevimab
- Where
- 7 sites in China
- Volunteers
- 816 people, healthy volunteers welcome
- Sponsor
- Han Tongyan
RSV Infection
The Impact of Age on Adaptive Immunity in Adults Infected With Respiratory Syncytial Virus
This study will for the first time systematically investigate the immune responses in an elderly cohort challenged with a well-defined RSV inoculum.
- Trial name
- INFLAMMAGE (NCT03728413)
- Testing
- RSV A Memphis 37
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
RSV Infection, hMPV
Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 Years
VAV00039 is a first-in-human (FiH) study to assess the safety and immunogenicity (in adult participants aged 60-75 years) after a single injection of different dose formulations of an RSV/hMPV vaccine candidate and RSV vaccine.
- Trial name
- NCT06583031
- Testing
- RSV/hMPV vaccine dose A1, RSV/hMPV vaccine dose A2, RSV/hMPV vaccine dose A3
- Where
- 6 sites in Australia
- Volunteers
- 385 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Respiratory Infection Virus, COVID -19
Preparedness Through Respiratory Virus Epidemiology and Community Engagement
The CHARM network will be established through three primary institutions-Beth Israel Deaconess Medical Center (BIDMC), the University of California San Diego (UCSD), and the University of Washington (UW)-along with their…
- Conditions
- Respiratory Infection Virus, COVID -19, RSV, FLU
- Trial name
- PREVENT (NCT07147517)
- Testing
- Component A0, Component A1, Component A2
- Where
- 2 sites in United States
- Volunteers
- 25,000 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
RSV Infection
A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model
A randomized, Phase 2a, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and antiviral activity of multiple doses of orally administered EDP-323 in healthy subjects infected with RSV-A Memphis 37b.
- Trial name
- NCT06170242
- Testing
- EDP-323 Dose Regimen 1, EDP-323 Dose Regimen 2
- Where
- United Kingdom
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Respiratory Syncytial Virus (RSV)
A Study to Assess Safety, Tolerability and Immunogenicity of RSVpreF From Multidose Vials in Healthy Female Adults.
Respiratory Syncytial Virus (RSV) is a common type of virus (germ) that can cause severe illness, where medical help is needed. RSV can lead to airway diseases in all ages. Vaccines help your body make antibodies.
- Trial name
- Amélie (NCT06473519)
- Testing
- RSVpreF MDV, RSVpreF SDV
- Where
- 6 sites in United States
- Volunteers
- 453 people, healthy volunteers welcome
- Sponsor
- Pfizer
Respiratory Syncytial Virus (RSV) Infection
A Phase 2 Study to Describe the Safety and Immunogenicity of Respiratory Syncytial Virus Vaccine IN006 in Healthy Participants Aged 60 Years and Older
The study will evaluate the safety, tolerability, and immunogenicity of 2 dose levels of IN006 in healthy participants who aged at 60 years or older; of a revaccination of IN006 given 12 months or 24 months after the initial…
- Trial name
- NCT07128121
- Testing
- Respiratory Syncytial Virus IN006 Bivalent mRNA Vaccine (IN006)
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Shenzhen Shenxin Biotechnology Co., Ltd
RSV Infection, QTc Interval
A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults
The purpose of the study is to assess the effect of a therapeutic and supratherapeutic dose of zelicapavir on the corrected cardiac QT interval relative to a placebo and positive control in healthy participants.
- Trial name
- NCT06601192
- Testing
- zelicapavir (therapeutic dose), zelicapavir (supratherapeutic dose), moxifloxacin
- Where
- 2 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc